Extract

This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.

Inclusion criteria

• Lymphoma, Large B-Cell, Diffuse ,Lymphoma. Non-Hodgkin

Country

• Australia
• Belgium
• Czech Republic
• France
• Germany
• Hungary
• Italy
• Poland
• Spain
• United States

Links

• nct
• ictrp